News
Videos
Conferences
Events
Resources
Subscribe

|Articles|October 1, 2014

Dana-Farber Leads Kadcyla ATEMPT Study in HER2-Positive Breast Cancer

Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.

Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Dan, a pancreatic cancer survivor

Stage 4 Pancreatic Cancer Survivor Shares Clinical Trial Path

BySpencer Feldman

December 18th 2025

Jace Yawnick, now in remission from non-Hodgkin lymphoma, is navigating the world of mental health one day at a time.

A Patient’s Journey Through Remission and Mental Health With Non-Hodgkin Lymphoma

December 17th 2025

Dr. Raghav Sundar

Expert Explains Nutrition and Weight Loss Challenges in Gastric Cancer

ByRaghav Sundar, M.B.B.S., M.R.C.P., M.Med.

December 16th 2025

Image of woman.

When Chemotherapy Side Effects Sent Her to the ICU

ByLindsey Gunter

December 16th 2025

Asian women who do not smoke in Northern California face rising lung cancer rates which are often diagnosed late due to current screening gaps.

Rising Lung Cancer Rates Targets Asian Women Nonsmokers in California

ByDr. Jeffrey B. Velotta

December 13th 2025

Trending on CURE

Rybrevant Faspro FDA-Approved as First Sub-Q Therapy for EGFR NSCLC

‘Full House’ Star Dave Coulier Talks Tongue Cancer Diagnosis

FDA Grants Regular Approval to Rubraca for Some With Prostate Cancer

Stage 4 Pancreatic Cancer Survivor Shares Clinical Trial Path

Padcev/Keytruda Combo Extends Survival in Muscle-Invasive Bladder Cancer